ARTICLE
2 July 2024

Changing Legal Environment Adds Uncertainty To ACLA Lawsuit Against FDA Over LDT Rule

M
Mintz

Contributor

Mintz is a litigation powerhouse and business accelerator serving leaders in life sciences, private equity, sustainable energy, and technology. The world’s most innovative companies trust Mintz to provide expert advice, protect and monetize their IP, negotiate deals, source financing, and solve complex legal challenges. The firm has over 600 attorneys across offices in Boston, Los Angeles, Miami, New York, Washington, DC, San Francisco, San Diego, and Toronto.
Of Counsel Benjamin Zegarelli spoke with GenomeWeb about an ACLA lawsuit against the FDA in connection with its final rule on laboratory-developed tests.
United States Food, Drugs, Healthcare, Life Sciences

Of Counsel Benjamin Zegarelli spoke with GenomeWeb about an ACLA lawsuit against the FDA in connection with its final rule on laboratory-developed tests.

Benjamin says, "My perspective on it is that the case for judicial deference to FDA under the current system without any changes would probably favor FDA's position to a certain extent. I'm not saying it would be a total slam dunk for FDA ... but the idea would be that under normal circumstances, as we've seen in the current state of jurisprudence, we should see courts deferring to FDA."

SOURCE

GenomeWeb

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More